Previous 10 | Next 10 |
- Data support differentiation of voclosporin as a potential best-in-class CNI - Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multip...
- Voclosporin ophthalmic solution (VOS) AUDREY trial results anticipated in the second half of 2020 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advanc...
Thesis to Investment: The likelihood that Aurinia Pharmaceuticals Inc.'s ( AUPH ) phase III trial, AURORA, succeeds is exceedingly low. The thesis to investment relies on a few vital prerequisites. The first being that the standard of care (SoC) for induction treatment of lupus nephritis ((L...
Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) , a clinical-stage biopharmaceutical company focused on rare diseases, were up 10% as of 11:05 a.m. EDT on Tuesday after management issued a press release that contained upbeat clinical and financial news. Management wanted to get three main...
- AURORA Phase 3 results with voclosporin for the treatment of lupus nephritis remain on track to be reported by the end of the fourth quarter 2019 - - Company provides commentary regarding at-the-market (“ATM”) facility - - AURORA II continuation study progressing a...
Gainers: Westwater Resources (NASDAQ: WWR ) +108% . TDH Holdings (NASDAQ: PETZ ) +74% . Reata Pharmaceuticals (NASDAQ: RETA ) +60% . Ra Medical Systems (NYSE: RMED ) +25% . Aphria (NYSE: APHA ) +25% . Abeona Therapeutics (NASDAQ: ABEO ) +25% . CannTrust Holdings (NYSE: CTST ) ...
Gainers : Ra Pharmaceuticals, Inc. (NASDAQ: RARX ) +100% . OncoSec Medical Incorporated (NASDAQ: ONCS ) +34% . ProPetro Holding Corp. (NYSE: PUMP ) +22% . Mereo BioPharma Group plc (NASDAQ: MREO ) +21% . Bed Bath & Beyond (NASDAQ: BBBY ) +20% . Caladrius Biosciences (NASDAQ: CLBS ...
Lupus nephritis ((LN)) is an inflammation of the kidney caused by an autoimmune disease called systemic lupus erythematosus (SLE) which affects mostly women. It is classified by different disease progression stages, and the symptoms are usually quite systemic, including fever, proteinuria, ede...
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “ Company ”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2, 2019 at 1:1...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late- stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that it has entered into an Open Market Sales Agreement wi...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...